Creating Stability In A Time Of Transition
An Interview With Syncona's Martin Murphy
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
You may also be interested in...
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.